For Cystic Fibrosis Patients, Targeted Bacterial Testing Could Decrease Premature Death

Cystic Fibrosis (CF) is the most frequent, lethal genetic disorder and occurs mainly from chronic lung disease caused by persistent airway pathogens that are detrimental to CF patients, such as Mycobacterium. Isolation of mycobacteria in the sputum of patients with CF has been significantly increasing over the past 15 years, especially resistant nontuberculous mycobacteria (NTM) strains. This is probably a consequence of a certain degree of immunoincompetence resultant from long-term antimicrobial treatment. For example, in total, 28 (7.44%) Mycobacterium spp. were isolated from 8 (6.15%) CF patients in Turkey, 5 (17.9%) were identified as Mycobacterium tuberculosis complex, 14 (50%) as Mycobacterium abscesses and nine (32.1%) as Mycobacterium lentiflavum. Additionally, all of these Mycobacterium tuberculosis complex isolates were susceptible to different types of antibiotics, such as streptomycin, isoniazid, rifampicin, and ethambutol. So, in pediatric CF patients, it should become common practice to preform specific mycobacterial analysis of sputum specimens and susceptibility testing, leading to decreasing the probability of premature death in CF patients.
Source :      2014/12/17 14:27

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
1/10 (تعداد آرا 1 نفر )
Copyright © 2011 AASM. All Rights Reserved.